logo
How this week's avalanche of news from Washington to Wall Street kept investors guessing

How this week's avalanche of news from Washington to Wall Street kept investors guessing

CNBC2 days ago
It was a dizzying week on Wall Street. The S & P 500 closed this past Monday at a record high and then went on a four-session losing streak. Friday was particularly unsettling as terrible jobs data slammed the market and triggered President Donald Trump . Trump started the day by slamming Federal Reserve Chairman Jerome Powell for not cutting interest rates on Wednesday. He accused the Fed of cutting rates at the end of last year to help elect Kamala Harris. Later in the day , the president used similar reasoning when firing the head of the Bureau of Labor Statistics, which puts out the employment report. Trump accused BLS Commissioner Erika McEntarfer, a Biden appointee, of negatively manipulating the numbers during his presidency and inflating them before Election Day to help Harris. Also on Friday afternoon, Fed Governor Adriana Kugler resigned . The Biden appointee didn't give a reason. As if all that were not enough, just before his self-imposed Aug. 1 deadline, Trump set new "reciprocal" tariff rates to go into effect on Aug. 7. The president also on Friday ordered two nuclear submarines "to be positioned in the appropriate regions" after a warning to the U.S. from Russian official Dmitry Medvedev. On Monday, Medvedev said that "each new ultimatum" about the Ukraine conflict is a "threat and a step towards war" between Russia and the U.S. .SPX .IXIC 5D mountain S & P 500 and Nasdaq performance this week It was no wonder the S & P 500 lost more than 1.5% on Friday, in a session even further pressured by a drop in tech stocks following Amazon 's post-earnings stock decline of more than 8%. For the week, the broad market index lost nearly 1%, ending a two-week win streak. The tech-heavy Nasdaq was the big loser Friday, dropping more than 2.2% on the session and more than 2% for the week. It, too, snapped two straight weekly gains. As bad as the calendar page turn to August was on Friday, the S & P 500 and the Nasdaq wrapped July on Thursday with gains of 2.2% and 3.7%, respectively. The S & P 500 completed a three-month winning streak, while the Nasdaq extended its monthly run to four straight. It was certainly a busy week, jam-packed with macroeconomic updates, trade negotiations, a Fed rate decision — and, of course, an earnings onslaught, with four of the Magnificent Seven reporting. Trump trade The week started out with the U.S. on Sunday striking a trade deal with the European Union. South Korea slipped in under the wire before the president's Friday deadline. Both trade partners are now subject to a 15% tariff on exports to the U.S., down from the respective 30% and 25% rates in place prior to the agreements. The deal with the EU will also see the trading bloc purchase $750 billion in U.S. energy, while investing an additional $600 billion into the U.S. The deal with South Korea included an agreement for $350 billion in U.S. investments. Negotiations with China remain ongoing, with the tariff deadline being pushed to Aug. 12. Mexico was granted a 90-day extension of current 25% rates following a discussion with Mexican President Claudia Sheinbaum. Canada, however, was slapped with a 35% tariff rate . As for the trade partners that have yet to strike a deal, new rates were announced last Thursday evening and are set to take effect this coming Thursday. Weak jobs Just hours after the new tariff rates were announced, the Friday jobs report was released. The July nonfarm payroll growth of 73,000 positions fell way short of the 100,000 additions economists had expected. Worse yet, the June and May readings were both revised significantly lower for a combined 258,000 less jobs than originally reported for those two months. All of that, besides setting Trump off, put a September rate cut back on the table, according to the CME FedWatch tool. The market odds of a cut flipped from about 38% on Thursday to nearly 83% on Friday. Shortly after the weak jobs report, Jim Cramer said that while he has been a big backer of Powell, this number says: "You didn't need to wait" to cut rates. Warmer inflation The day after the Fed held rates steady, the central bank's preferred measure of inflation — the personal consumption expenditure (PCE) price index — was released Thursday morning. Both the headline PCE reading, as well as the core rate excluding food and energy prices, came in one-tenth hotter than expected on a year over year basis, seemingly supportive of the Fed's decision to leave rates unchanged. However, the negative jobs data clouds the picture a bit and will force the Fed to weigh the importance of both parts of its dual mandate — maintaining price stability, around their target 2% inflation rate, and fostering maximum employment. The former currently requires more restrictive or higher rates, given that inflation remains above target, while the latter points to less restrictive or lower rates, because central bankers don't want to see any material increases in joblessness. Economic growth Part of the rationale for holding rates steady came from a strong advance second quarter reading on the economy, which was released Wednesday morning just hours before the Fed's July meeting wrapped up. The seasonally adjusted annual GDP growth rate of 3% was much better than the 2.3% advance that was expected. While the economy managed to chug along during the April to June period, despite all the fear and uncertainty caused by trade disputes, it's already August. The GDP is a backwards looking data set. That's why more weight is put on the monthly updates noted above, relating to inflation and the labor market — and of course, the most real-time source of data we can get, earnings. Club earnings So, with that, let's take a look at how earnings went this week for the Club. We heard from Starbucks on Tuesday evening, Meta Platforms and Microsoft on Wednesday evening, Bristol Myers Squibb on Thursday morning, Amazon and Apple on Thursday evening, and Linde on Friday morning. Starbucks : Though the coffee giant reported mixed quarterly results, we heard enough positives to confirm that CEO Brian Niccol's turnaround remains firmly on track. Meta Platforms : The social media powerhouse delivered an absolute blow out quarter, with the only thing better than the results being the guidance. Bristol Myers : The drugmaker delivered a solid quarterly beat and outlook raise. However, with the Cobenfy narrative — at the core of our investment thesis— going from being pretty straightforward to a show-me story, investors aren't giving the company the benefit of the doubt. We trimmed our price target following the release. There are also the added questions marks around Trump push this week for lower prescription prices from Bristol and 16 other major drugmakers, including Club name Eli Lilly, which reports earnings next week. The threat of sector-specific pharma tariffs remains in play. Amazon : Overall the tech giant reported a solid quarter. However, shares sold off as investors took issue with Amazon Web Services (AWS) failing to deliver the same type of cloud revenue upside as rivals Microsoft Azure and Google Cloud. Operating income guidance for the current quarter was also a bit lower than expected, though that has historically proven conservative. Ultimately, we think the concerns are overblown and think the pullback represents a buying opportunity . Apple : The iPhone maker reported a very respectable quarter. However, when taking into account the price action of the stock this year alongside the reaction to the results, it's clear that investors are not ready to give management much credit until they deliver more clarity about the company's AI strategy. It was encouraging to hear CEO Tim Cook say he's open to M & A to help with that. Linde : The industrial gas stalwart delivered solid quarterly results in a difficult operating environment, demonstrating the company's resiliency no matter the backdrop. Moreover, management raised the low end of its full-year earnings guidance, despite noting that the high end of the range already assumes an economic contraction. It's another important week of corporate earnings ahead, with about a quarter of S & P 500 companies set to report. Six companies in the Club portfolio are on the docket: Coterra Energy , DuPont , Eaton , Disney , Eli Lilly , and Texas Roadhouse . Week in trades It was also a busy week of trades for the portfolio. Kicking off the week, we added to our positions in Cisco Systems and Honeywell . That was followed up by a small trim of Eaton as the stock hit new high. On Tuesday, we locked in a nice profit on Eli Lilly following disappointing news from Novo Nordisk , its main competitor in the GLP-1 market. We also trimmed our position in Wells Fargo as shares finally recovered from their post-earnings decline. On Wednesday, we added to our position in Dover and called out that we would also be adding to our stakes in Starbucks and Palo Alto Networks , we were not restricted. We'll be keeping a close eye on both in the week to come for an opportunity to step in. Palo Alto finished the week down nearly 15% on a four-session losing streak after reports of talks and its confirmation of a $25 billion deal to buy CyberArk were not well received by investors. We, however, feel that bundling CybarArk's identity security platform will accelerate Palo Alto's platformization strategy. Rounding out the week , on Thursday, we cut our position in Abbott , in line with prior commentary in which we highlighted our concerns about the company's exposure to China. We took the raised capital and redeployed it in Capital One Financial as the move we were seeing in the stock didn't reflect the fundamentals we saw when it reported second quarter earnings. (See here for a full list of the stocks in Jim Cramer's Charitable Trust.) As a subscriber to the CNBC Investing Club with Jim Cramer, you will receive a trade alert before Jim makes a trade. Jim waits 45 minutes after sending a trade alert before buying or selling a stock in his charitable trust's portfolio. If Jim has talked about a stock on CNBC TV, he waits 72 hours after issuing the trade alert before executing the trade. THE ABOVE INVESTING CLUB INFORMATION IS SUBJECT TO OUR TERMS AND CONDITIONS AND PRIVACY POLICY , TOGETHER WITH OUR DISCLAIMER . NO FIDUCIARY OBLIGATION OR DUTY EXISTS, OR IS CREATED, BY VIRTUE OF YOUR RECEIPT OF ANY INFORMATION PROVIDED IN CONNECTION WITH THE INVESTING CLUB. NO SPECIFIC OUTCOME OR PROFIT IS GUARANTEED.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Zevra Therapeutics Announces Details for Q2 2025 Financial Results Call
Zevra Therapeutics Announces Details for Q2 2025 Financial Results Call

Yahoo

time12 minutes ago

  • Yahoo

Zevra Therapeutics Announces Details for Q2 2025 Financial Results Call

Company will host conference call at 4:30 p.m. ET, on Tuesday, August 12, 2025 CELEBRATION, Fla., Aug. 04, 2025 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare disease, today announced it will report corporate and financial results for the second quarter 2025 on Tuesday, August 12, 2025, via a news release after the market close, and will host a conference call/audio webcast at 4:30 p.m. ET that day. A link to the audio webcast will be accessible on the 'Events & Presentations' page in the Investor Relations section of Zevra's website at To join via telephone, please use the following dial-in information: (800) 245-3047 (United States) +1 (203) 518-9765 (International) Conference ID: ZVRAQ225 A replay of the webcast will be available for 90 days beginning at approximately 5:30 p.m. ET. The replay will be accessible on the 'Events & Presentations' page of Zevra's website at About Zevra Therapeutics, Inc. Zevra Therapeutics, Inc. is a commercial-stage company combining science, data, and patient needs to create transformational therapies for rare diseases with limited or no treatment options. Our mission is to bring life-changing therapeutics to people living with rare diseases. With unique, data-driven development and commercialization strategies, the Company is overcoming complex drug development challenges to make new therapies available to the rare disease community. For more information, please visit or follow us on X and LinkedIn. Caution Concerning Forward-Looking Statements This press release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include all statements that do not relate solely to historical or current facts, including without limitation statements regarding upcoming events or Zevra's participation at such events. Forward-looking statements are based on information currently available to Zevra and its current plans or expectations. They are subject to several known and unknown uncertainties, risks, and other important factors that may cause our actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. These and other important factors are described in detail in the "Risk Factors" section of Zevra's Annual Report on Form 10-K for the year ended December 31, 2024, filed on March 12, 2025, and Zevra's Quarterly Report on Form 10-Q for the quarter ended March 31, 2025, filed on May 13, 2025, and Zevra's other filings with the SEC. While we may elect to update such forward-looking statements at some point in the future, except as required by law, we disclaim any obligation to do so, even if subsequent events cause our views to change. Although we believe the expectations reflected in such forward-looking statements are reasonable, we cannot assure that such expectations will prove correct. These forward-looking statements should not be relied upon as representing our views as of any date after the date of this press release. Zevra Contact Nichol Ochsner +1 (732) 754-2545 nochsner@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Lindblad Expeditions (NASDAQ:LIND) Delivers Impressive Q2, Stock Soars
Lindblad Expeditions (NASDAQ:LIND) Delivers Impressive Q2, Stock Soars

Yahoo

time12 minutes ago

  • Yahoo

Lindblad Expeditions (NASDAQ:LIND) Delivers Impressive Q2, Stock Soars

Cruise and exploration company Lindblad Expeditions (NASDAQ:LIND) reported Q2 CY2025 results exceeding the market's revenue expectations , with sales up 23% year on year to $167.9 million. The company expects the full year's revenue to be around $737.5 million, close to analysts' estimates. Its GAAP loss of $0.18 per share was 21.7% above analysts' consensus estimates. Is now the time to buy Lindblad Expeditions? Find out in our full research report. Lindblad Expeditions (LIND) Q2 CY2025 Highlights: Revenue: $167.9 million vs analyst estimates of $159 million (23% year-on-year growth, 5.6% beat) EPS (GAAP): -$0.18 vs analyst estimates of -$0.23 (21.7% beat) Adjusted EBITDA: $24.84 million vs analyst estimates of $12.48 million (14.8% margin, 99% beat) The company lifted its revenue guidance for the full year to $737.5 million at the midpoint from $725 million, a 1.7% increase EBITDA guidance for the full year is $111.5 million at the midpoint, above analyst estimates of $107.6 million Operating Margin: 2.6%, up from -6% in the same quarter last year Free Cash Flow Margin: 8%, similar to the same quarter last year Market Capitalization: $641.7 million Natalya Leahy, Chief Executive Officer, said "I'm incredibly proud of the team's accomplishments this quarter. We delivered 23% revenue growth, achieved 86% occupancy on a 5% increase in capacity, and drove a 139% increase in Adjusted EBITDA. These results reflect strong momentum behind our strategic initiatives. We remain focused on unlocking meaningful value through continued revenue growth and disciplined cost innovation, and we are confident in the direction we're heading." Company Overview Founded by explorer Sven-Olof Lindblad in 1979, Lindblad Expeditions (NASDAQ:LIND) offers cruising experiences to remote destinations in partnership with National Geographic. Revenue Growth A company's long-term sales performance can indicate its overall quality. Even a bad business can shine for one or two quarters, but a top-tier one grows for years. Luckily, Lindblad Expeditions's sales grew at an impressive 22.2% compounded annual growth rate over the last five years. Its growth beat the average consumer discretionary company and shows its offerings resonate with customers. We at StockStory place the most emphasis on long-term growth, but within consumer discretionary, a stretched historical view may miss a company riding a successful new property or trend. Lindblad Expeditions's annualized revenue growth of 15% over the last two years is below its five-year trend, but we still think the results were respectable. This quarter, Lindblad Expeditions reported robust year-on-year revenue growth of 23%, and its $167.9 million of revenue topped Wall Street estimates by 5.6%. Looking ahead, sell-side analysts expect revenue to grow 9.1% over the next 12 months, a deceleration versus the last two years. This projection is underwhelming and suggests its products and services will see some demand headwinds. Here at StockStory, we certainly understand the potential of thematic investing. Diverse winners from Microsoft (MSFT) to Alphabet (GOOG), Coca-Cola (KO) to Monster Beverage (MNST) could all have been identified as promising growth stories with a megatrend driving the growth. So, in that spirit, we've identified a relatively under-the-radar profitable growth stock benefiting from the rise of AI, available to you FREE via this link. Operating Margin Lindblad Expeditions's operating margin has been trending up over the last 12 months and averaged 3.8% over the last two years. The company's higher efficiency is a breath of fresh air, but its suboptimal cost structure means it still sports lousy profitability for a consumer discretionary business. This quarter, Lindblad Expeditions generated an operating margin profit margin of 2.6%, up 8.6 percentage points year on year. This increase was a welcome development and shows it was more efficient. Earnings Per Share Revenue trends explain a company's historical growth, but the long-term change in earnings per share (EPS) points to the profitability of that growth – for example, a company could inflate its sales through excessive spending on advertising and promotions. Although Lindblad Expeditions's full-year earnings are still negative, it reduced its losses and improved its EPS by 18.3% annually over the last five years. The next few quarters will be critical for assessing its long-term profitability. In Q2, Lindblad Expeditions reported EPS at negative $0.18, up from negative $0.48 in the same quarter last year. This print easily cleared analysts' estimates, and shareholders should be content with the results. Over the next 12 months, Wall Street is optimistic. Analysts forecast Lindblad Expeditions's full-year EPS of negative $0.30 will reach break even. Key Takeaways from Lindblad Expeditions's Q2 Results We were impressed by how significantly Lindblad Expeditions blew past analysts' EBITDA expectations this quarter. We were also glad its EPS outperformed Wall Street's estimates. On the other hand, its full-year revenue guidance was in line. Overall, we think this was a solid quarter with some key areas of upside. The stock traded up 8.3% to $12.72 immediately after reporting. Indeed, Lindblad Expeditions had a rock-solid quarterly earnings result, but is this stock a good investment here? If you're making that decision, you should consider the bigger picture of valuation, business qualities, as well as the latest earnings. We cover that in our actionable full research report which you can read here, it's free.

Bruker (NASDAQ:BRKR) Reports Sales Below Analyst Estimates In Q2 Earnings
Bruker (NASDAQ:BRKR) Reports Sales Below Analyst Estimates In Q2 Earnings

Yahoo

time12 minutes ago

  • Yahoo

Bruker (NASDAQ:BRKR) Reports Sales Below Analyst Estimates In Q2 Earnings

Scientific instrument company Bruker (NASDAQ:BRKR). missed Wall Street's revenue expectations in Q2 CY2025, with sales flat year on year at $797.4 million. The company's full-year revenue guidance of $3.47 billion at the midpoint came in 1.5% below analysts' estimates. Its non-GAAP profit of $0.32 per share was 23.4% below analysts' consensus estimates. Is now the time to buy Bruker? Find out in our full research report. Bruker (BRKR) Q2 CY2025 Highlights: Revenue: $797.4 million vs analyst estimates of $809.2 million (flat year on year, 1.5% miss) Adjusted EPS: $0.32 vs analyst expectations of $0.42 (23.4% miss) Adjusted EBITDA: $68 million vs analyst estimates of $123.6 million (8.5% margin, 45% miss) The company dropped its revenue guidance for the full year to $3.47 billion at the midpoint from $3.52 billion, a 1.4% decrease Management lowered its full-year Adjusted EPS guidance to $2 at the midpoint, a 18% decrease Operating Margin: 1.5%, down from 6% in the same quarter last year Free Cash Flow was -$148.8 million compared to -$25.1 million in the same quarter last year Organic Revenue fell 7% year on year (7.4% in the same quarter last year) Market Capitalization: $5.76 billion Company Overview With roots dating back to the pioneering days of nuclear magnetic resonance technology, Bruker (NASDAQ:BRKR) develops and manufactures high-performance scientific instruments that enable researchers and industrial analysts to explore materials at microscopic, molecular, and cellular levels. Revenue Growth A company's long-term performance is an indicator of its overall quality. Any business can put up a good quarter or two, but many enduring ones grow for years. Thankfully, Bruker's 11.8% annualized revenue growth over the last five years was decent. Its growth was slightly above the average healthcare company and shows its offerings resonate with customers. We at StockStory place the most emphasis on long-term growth, but within healthcare, a half-decade historical view may miss recent innovations or disruptive industry trends. Bruker's annualized revenue growth of 12.6% over the last two years aligns with its five-year trend, suggesting its demand was stable. We can better understand the company's sales dynamics by analyzing its organic revenue, which strips out one-time events like acquisitions and currency fluctuations that don't accurately reflect its fundamentals. Over the last two years, Bruker's organic revenue averaged 4.8% year-on-year growth. Because this number is lower than its two-year revenue growth, we can see that some mixture of acquisitions and foreign exchange rates boosted its headline results. This quarter, Bruker missed Wall Street's estimates and reported a rather uninspiring 0.4% year-on-year revenue decline, generating $797.4 million of revenue. Looking ahead, sell-side analysts expect revenue to grow 3.2% over the next 12 months, a deceleration versus the last two years. This projection is underwhelming and suggests its products and services will face some demand challenges. Unless you've been living under a rock, it should be obvious by now that generative AI is going to have a huge impact on how large corporations do business. While Nvidia and AMD are trading close to all-time highs, we prefer a lesser-known (but still profitable) stock benefiting from the rise of AI. Click here to access our free report one of our favorites growth stories. Operating Margin Bruker has done a decent job managing its cost base over the last five years. The company has produced an average operating margin of 12.7%, higher than the broader healthcare sector. Analyzing the trend in its profitability, Bruker's operating margin decreased by 10.9 percentage points over the last five years. This performance was caused by more recent speed bumps as the company's margin fell by 12 percentage points on a two-year basis. We're disappointed in these results because it shows its expenses were rising and it couldn't pass those costs onto its customers. This quarter, Bruker generated an operating margin profit margin of 1.5%, down 4.5 percentage points year on year. This contraction shows it was less efficient because its expenses increased relative to its revenue. Earnings Per Share We track the long-term change in earnings per share (EPS) for the same reason as long-term revenue growth. Compared to revenue, however, EPS highlights whether a company's growth is profitable. Bruker's remarkable 10.4% annual EPS growth over the last five years aligns with its revenue performance. This tells us it maintained its per-share profitability as it expanded. In Q2, Bruker reported adjusted EPS at $0.32, down from $0.52 in the same quarter last year. This print missed analysts' estimates, but we care more about long-term adjusted EPS growth than short-term movements. Over the next 12 months, Wall Street expects Bruker's full-year EPS of $2.15 to grow 23%. Key Takeaways from Bruker's Q2 Results We struggled to find many positives in these results. Its full-year EPS guidance missed and its EPS fell short of Wall Street's estimates. Overall, this was a weaker quarter. The stock traded down 3.9% to $36.48 immediately following the results. Bruker underperformed this quarter, but does that create an opportunity to invest right now? We think that the latest quarter is just one piece of the longer-term business quality puzzle. Quality, when combined with valuation, can help determine if the stock is a buy. We cover that in our actionable full research report which you can read here, it's free.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store